Document is current
Any future updates will be listed below
-
Authors
Leal, Alessandro https://orcid.org/0000-0001-7967-3213
van Grieken, Nicole C. T. https://orcid.org/0000-0001-9992-0760
Palsgrove, Doreen N.
Phallen, Jillian
Medina, Jamie E. https://orcid.org/0000-0002-6124-0548
Hruban, Carolyn
Broeckaert, Mark A. M.
Anagnostou, Valsamo https://orcid.org/0000-0001-9480-3047
Adleff, Vilmos
Bruhm, Daniel C. https://orcid.org/0000-0002-8436-501X
Canzoniero, Jenna V.
Fiksel, Jacob
Nordsmark, Marianne
Warmerdam, Fabienne A. R. M.
Verheul, Henk M. W.
van Spronsen, Dick Johan https://orcid.org/0000-0003-1397-0236
Beerepoot, Laurens V. https://orcid.org/0000-0002-3040-4626
Geenen, Maud M.
Portielje, Johanneke E. A.
Jansen, Edwin P. M. https://orcid.org/0000-0002-8582-8100
van Sandick, Johanna
Meershoek-Klein Kranenbarg, Elma https://orcid.org/0000-0002-1750-2221
van Laarhoven, Hanneke W. M.
van der Peet, Donald L.
van de Velde, Cornelis J. H.
Verheij, Marcel
Fijneman, Remond https://orcid.org/0000-0003-2076-5521
Scharpf, Robert B.
Meijer, Gerrit A.
Cats, Annemieke
Velculescu, Victor E. https://orcid.org/0000-0003-1195-438X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA121113, CA233259, CA193145)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
EIF | Stand Up To Cancer (SU2C-AACR-DT1415)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Mark Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 16 October 2019
Accepted: 27 December 2019
First Online: 27 January 2020
Competing interests
: The authors declare the following competing interests: A.L., J.P., V. Adleff, and R.B.S. are founders of Delfi Diagnostics and own Delfi Diagnostics stock. V. Anagnostou receives research funding from Bristol-Myers Squibb. V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, a member of their Scientific Advisory Boards and Boards of Directors, and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. V.E.V. is an advisor to Bristol-Myers Squibb, Genentech, and Takeda Pharmaceuticals. Within the past 5 years, V.E.V. has been an advisor to Daiichi Sankyo, Janssen Diagnostics, and Ignyta. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies. The remaining authors declare no competing interests.
